CareDx, Inc (NASDAQ:CDNA) Shares Sold by Bank of Montreal Can

Bank of Montreal Can trimmed its position in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 32.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 392,819 shares of the company's stock after selling 191,770 shares during the quarter. Bank of Montreal Can owned approximately 0.73% of CareDx worth $11,667,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Royce & Associates LP raised its position in shares of CareDx by 0.3% during the 3rd quarter. Royce & Associates LP now owns 393,286 shares of the company's stock worth $12,280,000 after purchasing an additional 1,000 shares during the last quarter. Quest Partners LLC raised its holdings in shares of CareDx by 37.8% in the third quarter. Quest Partners LLC now owns 5,611 shares of the company's stock worth $175,000 after acquiring an additional 1,540 shares during the last quarter. Harvest Fund Management Co. Ltd purchased a new stake in shares of CareDx in the third quarter valued at $52,000. ClariVest Asset Management LLC boosted its stake in shares of CareDx by 2.9% during the second quarter. ClariVest Asset Management LLC now owns 64,027 shares of the company's stock valued at $994,000 after acquiring an additional 1,810 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in CareDx by 1,021.8% during the 2nd quarter. GAMMA Investing LLC now owns 2,210 shares of the company's stock worth $34,000 after purchasing an additional 2,013 shares in the last quarter.

CareDx Stock Up 4.5 %

Shares of NASDAQ CDNA traded up $1.10 during trading on Monday, hitting $25.64. 636,047 shares of the company traded hands, compared to its average volume of 893,637. The firm has a market capitalization of $1.38 billion, a P/E ratio of -9.50 and a beta of 1.80. The company has a 50-day moving average price of $25.51 and a 200-day moving average price of $22.67. CareDx, Inc has a 1 year low of $7.42 and a 1 year high of $34.84.

CareDx (NASDAQ:CDNA - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.11. The company had revenue of $82.88 million during the quarter, compared to analyst estimates of $80.04 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The firm's revenue was up 23.4% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.43) earnings per share. Research analysts predict that CareDx, Inc will post -0.7 EPS for the current fiscal year.

Analysts Set New Price Targets

CDNA has been the topic of several analyst reports. The Goldman Sachs Group raised their price target on shares of CareDx from $26.00 to $35.00 and gave the stock a "buy" rating in a research note on Wednesday, October 16th. BTIG Research decreased their target price on shares of CareDx from $40.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, November 5th. Wells Fargo & Company assumed coverage on CareDx in a report on Tuesday, August 27th. They issued an "underweight" rating and a $28.00 price target for the company. StockNews.com upgraded CareDx from a "hold" rating to a "buy" rating in a report on Thursday, October 17th. Finally, HC Wainwright reiterated a "neutral" rating on shares of CareDx in a research note on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, CareDx has an average rating of "Moderate Buy" and a consensus target price of $29.60.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.